DEFB118: A Potential Drug Target and Biomarker (G117285)

Target Name: DEFB118

NCBI ID: G117285

DEFB118

DEFB118: A Potential Drug Target and Biomarker

DEFB118 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to be involved in several physiological processes.Recent studies have suggested that DEFB118 may have potential as a drug target and biomarker. In this article, we will explore the potential of DEFB118 as a drug target and biomarker, and discuss its potential clinical applications.

Potential Drug Target

DEFB118 is a member of the superfamily of G-protein-coupled receptors (GPCRs), which are a family of G-protein-coupled receptor proteins that play an important role in cellular signaling. GPCRs are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling.

Studies have suggested that DEFB118 may be a potential drug target because it is involved in several physiological processes that are altered in various diseases, including diabetes, hypertension, and neurodegenerative disorders. For example, DEFB118 is involved in the regulation of insulin sensitivity and glucose metabolism, which are important for maintaining normal blood sugar levels. It is also involved in the regulation of blood pressure, which is important for maintaining cardiovascular health.

In addition, DEFB118 is involved in the regulation of pain perception and neurotransmission, which are important for maintaining brain health and function. Its involvement in these processes makes it a potential drug target for the treatment of pain, neurodegenerative disorders, and other conditions that are characterized by abnormalities in cellular signaling.

Potential Biomarker

DEFB118 is also potential as a biomarker because of its expression in various tissues of the body. Its expression has been observed in a variety of tissues, including the brain, heart, and kidneys. This suggests that it may be a useful biomarker for the diagnosis and monitoring of various diseases, including neurodegenerative disorders, diabetes, and hypertension.

In addition, DEFB118 has been shown to be involved in the regulation of cellular signaling processes, which may be relevant to its potential as a biomarker. For example, its expression has been shown to be involved in the regulation of neurotransmitter release and receptor function, which are important for cellular signaling. This suggests that DEFB118 may be a useful biomarker for the diagnosis and monitoring of cellular signaling disorders.

Potential Clinical Applications

The potential clinical applications of DEFB118 as a drug target and biomarker are vast and varied. One potential application is the treatment of pain, neurodegenerative disorders, and other conditions characterized by abnormalities in cellular signaling. For example, DEFB118 may be a useful drug target for the treatment of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, which are characterized by the progressive loss of brain cells and the development of behavioral and cognitive impairments.

In addition, DEFB118 may be a useful biomarker for the diagnosis and monitoring of pain, neurodegenerative disorders, and other conditions characterized by abnormalities in cellular signaling. For example, it may be used as a biomarker for the evaluation of the effectiveness of pain treatments, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). It may also be used as a biomarker for

Protein Name: Defensin Beta 118

Functions: Host defense peptide that exhibits antimicrobial activity against both Gram-negative bacteria, such as E.coli and S.typhimurium, and Gram-positive bacteria, such as S.aureus and B.subtilis (PubMed:15033915, PubMed:33224970). Inhibits cell adhesion of E.coli on intestinal epithelial enterocytes (PubMed:33224970). Causes rapid permeabilization of both the outer and inner membrane of E.coli, leading to morphological alterations on the bacterial surface (PubMed:15033915). Binds to bacterial lipopolysaccharides (LPS) with high affinity, and may thereby be involved in immunoregulation through LPS neutralization (PubMed:33181266). May contribute to epididymal innate immunity and protect the sperm against attack by microorganisms (PubMed:15033915)

The "DEFB118 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB118 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets